Total Funding
89
72
Total FundingPrivate Equity raised
Growth Score
0 pts
Heat Score
26 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Events
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
5918
Anagram Therapeutics develops orally delivered enzyme therapies for malabsorption syndromes and nutrient deficiencies.
Shenda Baker: Chief Science Officer & Board MemberPast Role: Synedgen, President & COO
William P. Wiesmann: Chairman
About the Company
Anagram Therapeutics is a clinical stage biopharmaceutical company focused on developing novel, orally delivered enzyme therapeutics. These therapies aim to treat serious diseases caused by malabsorption syndromes and nutrient deficiencies. The company is dedicated to advancing enzyme replacement therapies that are currently entering
clinicaltrials, particularly for conditions such as cystic fibrosis. Anagram Therapeutics leverages its expertise in biotechnology to create innovative solutions for unmet medical needs.
Women Founded
Women Led
